Quarterlytics / Financial Services / Asset Management / Sopheon Plc / FY1999 Annual Report

Sopheon Plc
Annual Report 1999

SPE · LSE Financial Services
Claim this profile
Ticker SPE
Exchange LSE
Sector Financial Services
Industry Asset Management
Employees 51-200
← All annual reports
FY1999 Annual Report · Sopheon Plc
Loading PDF…
A n n u a l   R e p o r t   1 9 9 9

providing the knowledge behind e-business

“ 1999 was a year of considerable progress for Sopheon and 

the year 2000 has begun well as we move towards fulfilling our

objective to become a major force in the global market for knowledge

management solutions. ”

contents

4

Group Profile

5

Chairman's Statement

8

Market and Product Overview

5
16

Group Profile
Directors and Advisers

5
17

Group Profile
Report on Directors' Renumeration

5
18

Group Profile
Directors’ Report

5
22

Group Profile
Statement of Directors' Responsibilities

5
23

Group Profile
Auditors' Report to the Shareholders

5
24

Group Profile
Group Profit and Loss Account

5
25

Group Profile
Group Balance Sheet

5
26

Group Profile
Company Balance Sheet

5
27

Group Profile
Group Statements of Cash Flows

5
28

Group Profile
Notes to the Accounts

4

GROUP PROFILE

Group Profile

Founded in 1993, Sopheon is an international software product development and

implementation company offering a range of proprietary business solutions in the rapidly

emerging field of knowledge management, with specific focus on the healthcare, life

sciences and high technology manufacturing sectors. Sopheon’s business solutions are

developed primarily using the company’s core technology components which are geared

to the rapid development of business applications, to support specific knowledge and

language intensive processes and functions. Sopheon also offers systems integration and

consultancy services for its software products and other complimentary products within

the knowledge management and web publishing markets.

The core technologies have resulted in the development of a generic, flexible software platform that

seeks to mirror the generic characteristics and structural aspects of knowledge and language intensive

processes and functions, and includes capabilities geared to the creation and maintenance of content

as well as its reuse, through a range of publishing techniques and applications.These can be applied and

customized to specific customer requirements through a range of standardized development

methodologies and tools, either by Sopheon directly or by its business partners.These business

partners include consultancy firms, system integrators and other software development companies.

The group has recently announced the proposed acquisition of Teltech Resource Network

Corporation, a knowledge management company based in Minneapolis, USA.

Sopheon has operations in the UK, the USA and the Netherlands and has approximately 

110 employees at the present time. It is quoted on the Alternative Investment Market (AIM) 

of the London Stock Exchange and the EURO.NM market of the Amsterdam Exchanges.

Chairman’s Statement

CHAIRMAN’S STATEMENT

5

“1999 was a year of considerable
progress for Sopheon and the year
2000 has begun well as we move
towards fulfilling our objective to
become a major force in the
global market for knowledge
management solutions.” 

Financial highlights
In line with expectations, revenue from the core business, including the
additional revenue from AppliedNet Limited which we acquired on 
22 November 1999, showed an increase in turnover of 70% to £1.5 million.
On an illustrative combined basis, the total revenue for AppliedNet and
Sopheon for the full year 1999 was £3.6 million, also in line with expectations.
Revenue for Teltech, the company proposed to be acquired by the Group, was
£10.1 million for 1999 which, also based on an illustrative combined basis, would
result in a revenue base for the enlarged group of £13.7 million for 1999. Sopheon
losses on an EBITDA (earnings before interest, tax, depreciation and amortisation)
basis were £1.7 million.We have adopted this approach for reporting on an ongoing
basis in line with common industry practice on both sides of the Atlantic.

Business development
The most significant business development during 1999 was the acquisition of the UK
knowledge management company, AppliedNet, which brought to the Group amongst
other important elements, a strong additional customer, revenue and
prospect base in the UK. With the integration of the former PolyDoc
and AppliedNet organizations into the new Sopheon completed in a
very smooth and expeditious manner, the Group is already starting to
experience accelerated commercial results.

Barry Mence
Executive Chairman

Amongst several other notable events, I would like to mention the
recent successful launch of the new FT.com (Financial Times online news website) in which 
Sopheon played an important role providing software and services, as covered in a recent 
Financial Times newspaper article. In addition to these and other business successes, and with 
good progress being made in our Healthcare business and a start in Life Sciences (Pharmaceutical
and Biotech), 1999 finished well and the year 2000 has started strongly in Europe. Our strategy to
become the de-facto standard in healthcare knowledge management software in the Netherlands
took a significant step forward in the early part of 2000 with our investment in Pro-GRAM BV,
a joint venture company with three of our major healthcare clients in the Netherlands. As I have
previously indicated Pro-GRAM is targeted with marketing solutions to the Dutch healthcare
industry, those solutions being based on our software and the knowledge content created by
teaching hospitals.

6

CHAIRMAN’S STATEMENT

In the months since the year end we have made very substantial strides in building on these
developments, as highlighted in our 3 March announcement of the proposed acquisition of 
Teltech Resource Network Corporation in the USA, and a now completed institutional placing 
for £20 million.

Our North American office in Denver has expanded rapidly with ten new staff joining in the last
few months and this, together with the substantial presence of Teltech in the USA, will I believe
position Sopheon exceptionally well in that market.

Product development
As discussed further in the Market and Product Overview the former PolyDoc focused on the
development and provision of content management and collaborative software solutions, based on
our proprietary IDP/A technology.This software was delivered as specific business solutions by
industry such as QualiFlow for Healthcare, NormFlow for Manufacturing, ResearchFlow for research
in Biotech and High-tech manufacturing.

Prior to acquiring AppliedNet, PolyDoc was looking to extend its software product range to
incorporate software that can gather, filter and disseminate information from both internal and
external sources. AppliedNet’s KnowledgeAgents software not only satisfies these needs, it also
profiles information automatically for distribution to individual users. Sopheon’s solutions moving
forward will now be drawing upon the integrated set of solutions and technology comprising both
IDP/A and KnowledgeAgents software, a very powerful and currently unique offering. Recently,
Doculabs (a Chicago-based software industry analyst firm) positively evaluated elements of our
Sopheon technology and gave verification of our integrated product strategy.

In the immediate future our product development efforts will be focused on enhancing this
integration as well as bringing the next generation of our industry-specific knowledge management
business solutions to market, utilizing these new capabilities. In addition, the inclusion of Teltech’s
portal technology and approach into the Sopheon product set should allow the Group to
significantly enhance its offering in the world of e-business and e-commerce.

Acquisition strategy
We first embarked on our acquisition strategy in 1998 with step one being the acquisition of
Lessenger in the Netherlands, which gave us over 50 healthcare software clients and ownership 
of a complementary software product. Step two was achieved with the acquisition of AppliedNet 
at the end of 1999, which gave us a more substantial customer base in the UK and ownership of
further complementary software. It also secured for us an established UK commercial organization
with strong product development and implementation groups, which are already providing a firm
base from which to further expand our business. As previously announced step three was targeted
to be in the USA in the year 2000 with the objective of obtaining similar benefits for the Group.
The proposed acquisition of Teltech in the USA, our most substantial to date, will satisfy all of 
our requirements for this. It will bring us a commercial organization with strong management and
over 100 additional personnel, a customer base that includes half of the Fortune 500 companies,
a substantial growing revenue base with a strong recurring element, and complementary technology.
This together with our strong software team already in place in Denver, will give us a firm footprint
into the North American market upon which to build.

CHAIRMAN’S STATEMENT

7

A large number of our clients operate on a global basis and they expect their suppliers to operate
in a similar way. This is in line with our own objective of becoming a global player in due course.
Therefore step four of our acquisition strategy is targeted at the Pacific Rim in the year 2001.
Other options are also being explored. However, the integration of Teltech and its technologies 
into the Group will take us through the summer and I will report to shareholders on these 
matters at that time.

Capital raising developments
I was pleased to announce in October last year that we had raised £8m to finance the development
of the enlarged group at the same time as we acquired AppliedNet in the UK. Earlier during 1999
we also raised £0.5m to invest in Pro-GRAM BV, a joint venture company with three of our major
healthcare clients in the Netherlands. I am confident that the acquisition of AppliedNet and the 
Pro-GRAM investment will make significant contributions to Sopheon’s future.

In March 2000 I was also able to announce the raising of an additional £20 million.These funds will
be used for the cash element of proposed acquisition of Teltech estimated at £10 million including
costs, and to further strengthen our working capital base to accelerate our sales and marketing
effort on both sides of the Atlantic.This successful institutional fund raising, which was achieved
together with our brokers Durlacher, has resulted in a number of existing investors enlarging their
holding in Sopheon and in a further number of top flight institutions becoming shareholders in the
Group. Durlacher has used all proceeds of commissions due under the placing to subscribe for
shares in Sopheon at the placing price.

I would like to welcome the new institutions to the company and to thank them for sharing our
confidence in Sopheon’s future. I would also like to extend this thank-you to all new and existing
shareholders who have retained or acquired shares during 1999 and the beginning of 2000.

Outlook
The full integration of the AppliedNet and Teltech businesses into the Group should ensure the year
2000 will be another year of substantial progress.With a growing customer base on both sides of
the Atlantic and a product and service offering that we believe has a considerable “first to market”
advantage, we have confidence that we are well positioned for considerable growth in a rapidly
growing market. In line with our customers’ requirements and Sopheon’s ambitions to become a
global player in the knowledge management market, we plan to continue to accelerate our progress
by acquisitions in further geographic locations as well as pursuing aggressive organic growth in each
of the territories where we operate today.

Barry K. Mence
Executive Chairman
28 April 2000

8

MARKET AND PRODUCT OVERVIEW

Market and Product Overview 

As a demand driven business, Sopheon has built expertise in areas where it perceives there are
commercial opportunities now and moving forward. Sopheon’s strategy is deliberately aligned 
to leverage existing expertise (for instance in healthcare, pharmaceuticals, biotechnology, high
technology manufacturing) but also gives a customer pipeline in a number of other key verticals
such as medical clinical guidelines, women’s healthcare, and pharmagenomics.

As an example, healthcare, on a global basis, has reached a crossroads. Over the last 10 years the
amount of electronic information stored and exchanged inside the healthcare system has rocketed.
Network based IT is increasingly the method by which this sector functions. Across Europe there
are numerous initiatives, which place technology at the center of the strategic development of
organized healthcare. Hospitals essentially manage both their medical and non-medical processes 
on the basis of procedures and guidelines, which form the basis of a de-facto body of instructions.

The application of these instructions is a key element in managing the quality and efficiency 
of healthcare institutions and is often decisive for clinical prognoses, liability claims, and issues
surrounding budgetary control.The guidelines are used for ongoing staff training, and dissemination
of information as well as in compiling checklists and treatment plans by the clinicians and nurses 
at the bedside.

Channel Strategy and Partners
The healthcare scenario in particular has underpinned Sopheon’s sales during 1998 and 1999, with 
a major order for Sopheon’s healthcare solution, delivered through Pro-GRAM BV, a joint venture
between three Dutch teaching hospitals which Sopheon has itself joined in 2000 as a 25% partner.

Outside of the Pro-GRAM channel in the Netherlands, the group has already worked with major
consultancy practices in developing solutions for knowledge management.This includes KPMG and
IBM.Whilst these relationships will continue to be important and welcome, there is an opportunity
to fast-track the channel strategy in a more proactive manner.We believe that for the next 
12-18 months a strategy of alliances with specialist, vertically oriented systems integrators or
national consulting practices of complimentary software vendors is the best way forward.
This will allow us to:

build a customer base producing revenues.
reduce management overhead in terms of individual customers.

(cid:2) move toward critical mass in building a customer base, which will make us an interesting
proposition for the global systems integration companies who can provide volume sales.

The first phase of this strategy has already been implemented with the signing of an agreement 
with Marlow Consulting in the UK for the marketing and sales of Sopheon software into the
healthcare and manufacturing sectors. In addition, in the USA we will look to aggressively 
leverage the proposed Teltech acquisition having previously signed up Teltech as a business 
partner earlier in 1999.

(cid:2)
(cid:2)
MARKET AND PRODUCT OVERVIEW

9

We are also planning discussions with a small number of software suppliers with substantial
customer bases with a view to integrating modules into their offerings. Such an agreement 
has recently been signed with a leading Italian ERP specialist, Gruppo Formula.We have also 
entered into an agreement with Hiscom in the Netherlands whereby it will collaborate on medical
knowledge systems, to accelerate the development of electronic patient dossiers. Hiscom is the
leading medical IT supplier in the Netherlands and is increasingly marketing such solutions in other
markets, in particular, the Belgium and the Scandinavian countries.

Products
The core Sopheon solutions are based on the proprietary Integrated Document Production
Architecture (IDP/A), which forms the foundation of a comprehensive range of software products.
In this product architecture, the key points to note are that the creation and maintenance activities
are distinct from the access to published material and searching processes. International patents for
IDP/A were applied for in 1996 under the Patent Cooperation Treaty process.

Prior to acquiring AppliedNet, PolyDoc was looking to extend its software product range to
incorporate software that can gather, filter and disseminate information from both internal and
external sources. AppliedNet’s KnowledgeAgents software not only satisfied these needs, it also
offered profiling of information automatically for distribution to individual users. This is described
further below under Sopheon Agents™.

In addition, the period leading up to and since the acquisition of AppliedNet has seen significant
progress in the branding and accessibility of the former PolyDoc software products. PolyDoc had
established the XFlow suite based on its core IDP/A technology, and recent developments have
made the following elements available as separate modules:

Sopheon Composer™
Authoring Support to allow the content creating community in a specific process to build an
advanced, maintainable and high quality knowledge database for multiple publication purposes.
This support includes advance language tools to help the writing of well-structured, linguistically
correct and consistent texts. Furthermore the tools support the creation of metadata, keywords,
references (links) and terminology marking. A strong element of authoring support is the so-called
Terminology Checker, which supports authors and editors in checking their choice of wording
against a central terminology database.Translation facilities are integrated in the environment.

Sopheon Publishing™
Publishing and Search Support to allow optimal and multiple reuse of the content, which includes
historical output formats as well as web enabled access and search facilities, serving a range of
“readerships”. Sopheon’s publishing function offers a highly communicative environment for the
readerships. For example, terms in texts are highlighted and can be clicked by the reader in 
order to see their meaning and other background information in their original historical context.
The search functionality is highly linguistic-oriented and allows the usage of thesauri and rhetorical
structures as a basis for very specific and personalized reuse of content across disciplines, domains,
processes and even languages.With this function Sopheon can apply any modern search technique
and is able to connect with a range of search engines, though with the AppliedNet acquisition much
of this technology now resides in house.

10

MARKET AND PRODUCT OVERVIEW 

Sopheon Terms™
Terminology Management Support to enable a central function, to take care of the harmonization,
storage and maintenance of the terminology of specific processes.This function is a key element 
of Sopheon’s approach to help the process community to communicate efficiently and effectively,
avoiding expensive misunderstandings. From the Terminology Database there is an output stream 
of data into other functions, for example, lookup dictionaries, the spell checker, the term checker,
but also into the advanced search facilities (through the generation of thesauri) and into web pages.
This tool is also a key element for managing the integration with other systems such as Enterprise
Resource Planning (ERP) systems and specific Electronic Document Management Systems (EDMS).

Sopheon Modeler™
In order to enable the Sopheon IDP/A solutions to be rapidly customized for individual customers 
a set of configuration tools have come through the product development planning pipeline, and will
be introduced under the name Sopheon Modeler. These tools are designed to improve the speed
and ease with which both channel partners and customers can perform customization of the
Sopheon IDP/A suite for their own specific requirements.

Sopheon Agents™
Sopheon Agents is designed as a central corporate knowledge base that can act as both the
repository and the “broker” for information stored within the corporate memory. The product
provides the ability to gather, filter, and disseminate information from both internal and external
sources, while also profiling that information automatically for distribution to individual users.

Sopheon Agents allows users to define a profile on a subject that is critical to their work, defining 
a vocabulary of interest as this is created. That vocabulary becomes a set of triggers that are 
then used to identify the right information. Hunting through the corporate knowledge base,
Sopheon Agents delivers information to the desktop, either via e-mail or as a special Internet page.
Sopheon Agents can also make use of external information feeds and the Internet. Users can have
more than one profile of interest simultaneously.

The components described above enable the delivery of applications that can be deployed in a 
wide variety of enterprise situations. Sopheon has developed and is developing the following 
range of vertical application solutions using the IDP/A technologies:

Sopheon for Life Sciences
Sopheon for Research & Development
Sopheon for Healthcare

Sopheon has several healthcare solutions.

Sopheon for Healthcare – Qualiflow™
This solution enables hospitals and healthcare organizaitons to create, maintain and publish medical
protocols and healthcare quality documents. This was a major revenue contributor during 1998 and
1999, delivered through Pro-GRAM BV, the joint venture between three Dutch teaching hospitals
which Sopheon has itself joined in 2000.

MARKET AND PRODUCT OVERVIEW 

11

Sopheon for Healthcare – Lessenger™
This simple but effective document management solution supports the specific compliant 
version control and regulatory distribution procedures required for certification of laboratories,
food processing plants, sections of the pharmacy, and other areas within the healthcare industry.
Input is from standard word processors while publishing can be on paper – the appropriate 
headers and footers are added and distribution lists are generated automatically, or electronic –
viewing either through intranet browsers or through special viewers.

Internet
Sopheon has positioned itself to benefit from developments in the Internet marketplace over 
the next 24 months.

At present (due to the fact that intranets and extranets are so central to the Knowledge
Management proposition) the software as a matter of course allows users to reuse content from
the knowledge repositories which have been created using IP, through a web interface. The next
stage in the development of the business is to allow content creation to be done through a web
interface. Modes of input will always be based on XML, on which Sopheon has built its content
management strategy moving forward, making our products fully interoperable and reducing any
possible concerns with regard to interconnectivity. From a competitive perspective this allows us 
to see how the market emerges without having to place a single large bet on any single vendor.

We also plan to enter the newly emerging application service (ASP) space. Knowledge management
software is an ideal candidate for ASP hosting in that the commercial model for the service delivers
positively on two key IT deployment concerns, return on investment and total cost of ownership.

Ongoing Developments
Sopheon’s solutions moving forward will now be drawing upon the integrated set of solutions 
and technology comprising both the IDP/A and Sopheon Agents software, a very powerful and
currently unique offering. Recently, Doculabs (a Chicago-based software industry analyst firm)
positively evaluated elements of our Sopheon technology and gave verification of our integrated
product strategy.

In the immediate future our product development efforts will be focused on the integration 
of these solutions as well as bringing the next generation of our industry-specific knowledge
management business solutions to market, utilizing these new capabilities. In addition, the 
inclusion of Teltech’s portal technology and approach into the Sopheon product set should allow
the Group to significantly enhance its offering in the world of e-business and e-commerce.

A product development plan and delivery schedule is in place to continue the enhancement of the
Sopheon IDP/A components and to bring the first levels of IDP/A and Sopheon Agents integrated
technology to the market during Q2 and Q3 of the current year. This will be deployed through the
existing industry-specific Sopheon application solutions (such as Sopheon for Healthcare) and also
by the next generation of Sopheon solutions that is currently in the development planning process.

12

MARKET AND PRODUCT OVERVIEW 

Integrated Solution Overview – Sopheon

Sopheon Modeler ™
Web-based, thin client solution for creating
and managing Content and Content Structures
in real time.

Sopheon Terms ™
Solution for Terminology Management across the 
Sopheon Suite. Sopheon Terms™ provides interactive
navigation of Terminology Relationships, Glossaries and
Dictionaries. Sopheon Terms™ is fully enabled to support
authoring and terminology management across languages
and content versions.

Sopheon Composer ™
Content capture solution which enables Guided
Authoring with Controlled Workflow across 
Multiple Languages. Sopheon Composer™ allows
comprehensive Metadata and Keyword search across
the entire knowledge base.

Sopheon Agents ™
Enables gathering, filtering, and dissemination of information
from a variety of external and internal sources including the
Internet, Intranets, Groupware solutions, and virtually any file
structures. Sopheon Agents™ provides robust search facilities
with the ability to ensure that only relevant information is
returned. Communities of interest and project teams can
collaborate on and across content within the shared knowledge
base. A staff profile is developed, enabling identification of
interests, skills, and capabilities.

Sopheon Publisher ™
Allows content to be automatically published to key web resources
including Intranets, Portals and any e-business application. It is also
an ideal solution for creating Manuals, Reports, Research Studies 
and any Complex Document Formats. Also included in Sopheon
Publisher™ is the ability to export to other technologies such as
intelligent pagers and Personal Digital Assistants (PDA’s).

WHAT BENEFITS CAN BE EXPECTED?

13

Vertical Solutions

Sopheon provides solutions which are tailored to the best
practices and requirements of specific vertical industries.
These include the following vertical solutions:

Sopheon for Healthcare
Sopheon for Healthcare is specifically designed with the challenges faced by healthcare providers in
mind. Included are the following modules specifically designed to bring excellence to the point of
care:

(cid:2) Quality Manuals
(cid:2) Managerial Policy Guidelines
Administrative Procedures
Laboratory Standard Operating Procedures

(cid:2) Nursing Protocols
Clinical Guidelines
Food Procedures & Instructions
Logistical Procedures
Pharma Procedures

Sopheon for Life Sciences
Enterprises in the Life Sciences industries face the dilemma of increased competition, the need 
to reduce product development times and simultaneously embrace new technology and markets.
These crucial forces will govern whether or not they are to win or lose. The real competitive
advantage lies in getting more products to market, faster. Sopheon for Life Sciences is designed 
to collect information from the outset in a controlled and managed process, regardless of where 
that information is created. The created information and knowledge may be stored, published 
and reproduced in a variety of formats and styles. Its structured storage will allow the information
to be queried and reused in many different ways throughout the extended community. By enabling
collaboration, content gathering, and publishing of specialized content, Sopheon helps your company
to work smarter and reduce the time taken for discovery and analysis.

Sopheon for Research & Development
Research & Development organizations face tough challenges as they seek to shorten the time 
it takes to bring products to market. This is accomplished in part by reducing non-productive
administration time, allowing the creation of time for knowledge professionals to add greater 
value through innovation and creativity. This challenge is compounded by the vast mountain of
information which exists on external resources. Sopheon for Research & Development enables
content and knowledge collaboration across individuals, projects and communities. The result is 
an organization which is in touch with science and technology resources and much more.
The following is just a sampling of the list of capabilities in Sopheon for Research & Development:

Research Reporting
Testing Reporting
Scientific Articles
Best Practices
Safety and Materials Handling
Incident Management Procedures

(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
(cid:2)
14

MARKET AND PRODUCT OVERVIEW 

Knowledge Makes All the Difference
Never before has so much information been within the reach of today’s professional. With the
maturity of corporate information stores, libraries, and the Web, the sheer volume and scale of
these resources are just now being realized.

Where is the value in this enormous volume of information? Businesses today are valued not only
by what they produce in terms of goods and services, but also the accumulated knowledge which
enables their core business. It is essential for organizations to be able to have a clear understanding 
of the value of knowledge assets, similar to how they value assets such as capital equipment and
real estate.

Consider the generation of new, original content by your organization. What happens to content
which is created by your valued Knowledge Workers? Your organization should be able to
continuously derive benefit from shared knowledge and create an environment for innovation.
The organization should benefit from the shared knowledge base and not be limited to an
individual’s file stored on a local desktop. What happens when that individual leaves the company…
does the knowledge walk out the door along with them? A solution is needed which supports the
continuous capture of knowledge and expertise and provides the knowledge base to make it
available across the organization’s communities.

The ability to survive in a global environment is essential. Today’s organizations are becoming
decentralized and must enable knowledge assets to transcend language and geographical barriers.
Sopheon was conceived in a multilingual, multinational environment in order to remove boundaries
which separate knowledge from the people who need it. Only Sopheon provides knowledge
solutions with core multilingual and localized content capability.

Content with Context
Simple search engines attempt scanning and categorization of such sources, but have fallen short in
one key area: context. Without understanding context, one cannot make the leap from information
to knowledge with meaning. The understanding of the context in which language is used is perhaps
just as important as the understanding of the meaning of a simple word. Consider a simple search
for the word manifold. Without knowing the context in which you want to search, you’ll encounter
everything from rock bands to exhaust handling products. By searching within the context of
distributors of compressed medical gas brass manifolds, you find exactly what you’re looking for.
In a similar example, an operator at a major petrochemical plant needs to find out how to shut
down a manufacturing process. Without being aware of the context of the search, perhaps that 
the plant is on fire, the operator may encounter information which has nothing to do with their
immediate need.

MARKET AND PRODUCT OVERVIEW 

15

What Benefits can be expected with a Sopheon solution?

Improved Business Strategy
The entire organization can have access to the critical business and technical information necessary
for effective, strategic decision making. Sopheon Knowledge Solutions not only allow access to
content, they provide the environment for creation of better content.

Create the Environment for Innovation
Never before has collaboration been so essential to an organization’s success. Collaboration is 
of particular necessity in today’s virtual organizations, with team members and groups working
together across geographies, time zones, and languages. Sopheon allows collaboration across and
within communities of interest and enables those participants to enrich the value of that content.

Faster Time to Market
Quicker access to information shortens product development cycles. Ready access to mission
critical information and knowledge can shorten product development cycles by as much as 30%.
This is delivered by both getting the right answers faster and also perhaps equally important:
knowing what not to do, in a rapid manner.

Improved Profitability
Sopheon can deliver economies in procuring and delivering knowledge. These economies can be
realized through more effective utilization of internal and external resources.

Best Practices and Process Improvement
Sopheon solutions ensure the organization captures and reuses best practices helping to reduce 
and eliminate redundant and unnecessary activities. By implementing best practices key knowledge
workers can now focus on creativity – delivering increased productivity and innovation.

Creation of Knowledge Assets
Increasingly organizations must be able to demonstrate how they capture and quantify their
intellectual assets. The value of today’s leading organizations is based more upon their intellectual
capital than the traditional “brick and mortar” measures. Knowledge has become your most 
critical asset.

16

DIRECTORS AND ADVISERS

Directors and advisers

Directors

Barry K. Mence
Richard V. Maddocks
Huub J.M. Rutten, Drs.
James M Macfarlane, CENG
Arif Karimjee, ACA
Hans Coltof, Dr.
Stuart A. Silcock, FCA
Michael J. Brooke

Executive Chairman 
Managing Director 
Product Research Director 
Business Development Director
Finance Director
Non Executive Director 
Non Executive Director 
Non Executive Director

Secretary

E.R.E. Iljitsj Wiebenga, CA (SA)  

Registered office

Stirling House, Surrey Research Park
Guildford
Surrey GU2 5RF

Registered number

Registered in England and Wales:

3217859

Auditors

Principal bankers

Solicitors

Ernst & Young 
Apex Plaza 
Reading RG1 1YE

Rabobank Amsterdam b.a.
Wilhelminaplantsoen 124 
1111 CP Diemen 
The Netherlands

Edge Ellison
18 Southampton Place
London WC1A 2AJ

Lloyds Bank Plc
77 High Street
Southend-on Sea
Essex SS1 1HT

Nauta Dutilh
Prinses Irenestraat 59
1077 WV Amsterdam
The Netherlands

AIM Nominated Adviser

Brewin Dolphin Securities Limited
48 St.Vincent Street
Glasgow G2 5TS

AIM Nominated Broker

Durlacher Limited
4 Chiswell Street
London EC1Y 4UP

Registrars

Independent Registrars Group Limited
Balfour House 390/398 High Road
Ilford
Essex IG1 1NQ

Financial PR Consultants

Buchanan Consultants
107 Cheapside
London
EC2V 6DN

REPORT ON DIRECTORS’ REMUNERATION

17

Report on Directors’ Remuneration

The remuneration committee of Sopheon Plc is responsible for oversight of the contract terms,
remuneration and other benefits for executive directors, including performance related bonus schemes.
The committee comprises the non-executive directors together with Barry Mence. The committee 
makes recommendations to the board, within agreed parameters, on an overall remuneration package 
for executive directors and other senior executives in order to attract, retain and motivate high quality
individuals capable of achieving the group’s objectives. The package for each director consists of a basic
salary, benefits and pension contributions, together with performance related bonuses and share options
for certain directors on a case by case basis. Consideration is given to pay and employment policies
elsewhere in the group, especially when considering annual salary increases. In addition, the committee is 
in the process of taking advice from a leading firm of remuneration consultants to maximize comparability
within the marketplace.

Contracts
Service contracts between the company and the executive directors are terminable on 6 months notice.

Fees for non-executive directors
The fees for non-executive directors are determined by the board. The non-executive directors are 
not involved in any discussions or decisions about their own remuneration.

Directors remuneration
Set out below is a summary of the fees and emoluments received by all directors during the year.
Details of directors’ interests in shares and options are set out in the Directors’ Report.

Executive directors

B.K. Mence
R.V. Maddocks
H.J.M. Rutten
E.R.E.I.Wiebenga (1)
J.M. Macfarlane (2)

Non-executive directors

M.J. Brooke (2)
S.A. Silcock
H. Coltof
D. Geest

Basic salary
and fees
£

67,356
78,016
58,511
31,207
8,253

Bonus
£

-
-
-
-
2,885

Benefits
£

Contributions
to Pension
£

Total
1999
£

Total
1998
£

11,808
16,115
11,050
7,803
1,731

3,000
6,876
2,701
1,440
825

82,164
101,007
72,262
40,450
13,694

82,730
101,841
73,957
41,314
-

1,000
31,818
6,200
-
––––––––
282,361
––––––––

-
-
-
-
––––––––
2,885
––––––––

-
-
-
-
––––––––
48,507
––––––––

-
-
-
-
––––––––
14,842
––––––––

1,000
31,818
6,200
-
––––––––
348,595
––––––––

-
35,021
6,300
6,272
––––––––
347,435
––––––––

(1) Resigned on 1 February 2000
(2) Appointed on 22 November 1999
(3) Pension contributions are made to individual directors personal pension schemes.

The emoluments of S.A. Silcock and M.J. Brooke are paid respectively to Lawfords Limited,
of which Mr Silcock is a director, and Coinshire Limited, of which Mr Brooke is a director.

18

DIRECTORS REPORT

Directors Report

Financial Results
The result for the year ended 31 December 1999 both before and after taxation is a loss of £2,072,000
(1998 – £1,142,000 restated) on a turnover of £ 1,510,000 (1998 – £891,000). The directors do not
propose to declare a dividend.

Principal Activities
The group’s principal activities during the year continued to be the development and provision of
knowledge management software, solutions and services.

Review of the Business
Including revenue from AppliedNet Limited which we acquired on 22 November 1999, turnover showed
an increase of 70% to £1.5 million. This included £874,000 from the former PolyDoc business, a significant
proportion of which is represented by healthcare related sales as in 1998. Exceeding expectations and
historic performance, a large part of the post acquisition revenues of £636,000 recorded for AppliedNet
resulted from a major customer implementation that required rapid expansion of resources. On an
illustrative combined basis, the total revenue for Sopheon including AppliedNet for the full year 1999 
was £3.6 million. Sopheon losses on an EBITDA basis (earnings before interest, tax, depreciation and
amortisation) were £1.7 million.

The North American office in Denver has expanded rapidly with ten new staff joining in the last few
months.

The acquisition of AppliedNet Limited was satisfied by an issue of ordinary shares at a market price per
share of 129p, which together with costs resulted in a total acquisition cost of £8,439,000. At the same
date an institutional placing of shares for cash raised £7,699,000 after costs to be used to fund the
development of the combined businesses. The structure of the acquisition required the share capital of the
Company to be restructured such that each ordinary share of 20p was converted into one ordinary share
of 5p and one deferred share of 15p, as described more fully in note 17.

Changes in accounting policies and allocations
Historically, development expenditure incurred for specific products was capitalized when its future
recoverability could reasonably have been regarded as assured, and amortized in line with the expected
future sales from the related product, to a maximum of 5 years. Following the acquisition of AppliedNet
Limited and subsequent harmonization of group accounting policies, all such expenditure is now written 
off as incurred. The effect of changing this policy has been reflected by way of a prior year adjustment to
the 1998 financial statements of the group. Had the previous policy been continued, the results for 1999
would have shown a reduction in losses for the year of £7,000.

Furthermore, the directors have also taken the opportunity to revise the allocation of certain costs
between categories within the profit and loss account. These mainly relate to internal management and
research and development activities, which have been reallocated from cost of sales to administrative
expenses and is described further in note 3.

Future Developments
Sopheon will continue to build its strategy of becoming a global force in knowledge management solutions
through both organic and acquisition routes. The acquisition of AppliedNet Limited in the UK has given the
group new software, critical mass and a platform for expansion in Europe. The proposed acquisition of
Teltech Resource Network Corporation, announced in March 2000, is expected to deliver similar benefits
in the USA as well as significantly enhancing the breadth of product and service that the group can offer.
Effort will continue to be directed at the integration and verticalization of the group’s software assets and
new product releases are planned for later in 2000. As mentioned in the Chairman’s statement, the group
will look for acquisition opportunities in the Pacific Rim in 2001.

Research & Development
In the area of information and language technology Sopheon continues to invest in research to ensure the
group’s products and core software remain at the leading edge of proven technologies. The linguistic
research team in Maastricht remains a cornerstone of the group’s intellectual property resource. In addition,
the capability to direct effort at development activities has been increased by the acquisition of AppliedNet,
which had a development team of thirteen people, as well as the ongoing expansion of Sopheon’s Denver
based team where there are now five development staff including Paul Heller, our Chief Technology Officer.

DIRECTORS REPORT

19

Core research activities include the Integrated Terminology Management Cycle (ITMC) research project
being partly funded by European Union’s Eureka programme. The ITMC project will draw to a close in
2000. Discussions are underway with the relevant authorities to secure participation by the group in
further Eureka projects. In addition, the group has joined with other partners including Italian ERP 
vendor Gruppo Formula to participate in the European Union’s Leveraging Operational Resource
Enterprise (LORE) project.

Directors and their interests
The directors interests in the share capital of the Company (all beneficially held except those marked with
an asterisk, * which are held as trustee), were as follows:

Director

Share Options
1998

1999

Ordinary Shares
1998

1999

B.K. Mence
R.V. Maddocks
H.J.M. Rutten
E.R.E.I.Wiebenga (resigned on 1 February 2000)
S.A. Silcock
S.A. Silcock*
H. Coltof
J.M. Macfarlane
M.J. Brooke
A. Karimjee (appointed on 1 February 2000)

-
400,000
-
-
-
-
100,000
-
-
100,000

-
400,000
-
-
-
-
100,000
-
-
-

8,337,800
25,000
507,500
340,000
192,450
107,010
-
1,719,716
691,724
-

8,337,800
25,000
507,500
340,000
192,450
107,010
-
-
-
-

Of the 8,337,800 Ordinary Shares mentioned above B. K. Mence beneficially owns and is the registered
holder of 4,490,000 Ordinary Shares. He is, or his wife or children are, potential beneficiaries under trusts
holding an aggregate of 3,847,800 Ordinary Shares of which trust directors of Lawfords Ltd., in the Isle of
Man, are trustees and are registered as the holders of such shares. S.A. Silcock is a shareholder in Lawfords
Ltd. in the Isle of Man. At 31 December 1998 and 1999 B K Mence also held £523,640 5% Convertible
Loan Stock at par and warrants to subscribe on or before 31 December 2000 for 300,000 Ordinary
Shares at £1.46 per share. If not exercised by that date the warrants shall lapse.

Both Mr Maddocks’ and Mr Coltof’s options have an exercise price of 20p and are exercisable at any 
time before 17 July 2001. Mr Karimjee’s options have an exercise price of 150p and are not exercisable
until 22 November 2002. Furthermore, the vesting of 50,000 of his options is linked to agreed
performance criteria.

No directors exercised share options during the period. Since the year end, Mr Maddocks and 
Mr Coltof exercised all of their options to acquire shares in the Company. On 10 March 2000,
Mr Maddocks, Mr Silcock and Mr Rutten each sold 25,000 of their shares in the Company.

On 28 July 1998, the Company issued £1,570,920 5% Convertible Loan Stock 1999 (“Convertible 
Loan Stock”). £523,640 of the Convertible Loan Stock was subscribed for by Barry Mence following
independent shareholders’ approval as required by The Panel on Takeovers & Mergers (“the Panel”).
Following agreement between the Company and the Loan Stockholders, including Barry Mence, the
redemption date and the conversion date for the Convertible Loan Stock has been moved from 
31 July 1999 to 31 July 2000.

The midmarket share price ranged from 126p to 405p during the financial year.

Save as disclosed above, no Director (or member of his family) or connected persons within the 
meaning of Section 346 of the Companies Act 1985 has any interest, beneficial or non-beneficial,
in the share capital of the company.

20

DIRECTORS REPORT

Substantial Shareholdings
The Directors are aware of the following persons who as at 28 April 2000 are interested directly or
indirectly in three per cent or more of the company’s issued Ordinary Shares:

Name
Brandon Limited
B.K. Mence (director)
J.M. Macfarlane (director)

No. of
Ordinary
Shares
1,793,647
8,337,800
1,719,716

% issued 
Ordinary
Shares
5.1
23.7
4.9

Mr Mence’s interest represents direct beneficial holdings as well as those of his family.

Share Option Schemes
Details of options granted are shown in note 17.

Creditor payment policy and practice
It is the company’s policy that payments to suppliers are made in accordance with those terms and
conditions agreed between the company and its suppliers, provided that all trading terms and conditions
have been complied with. At 31 December 1999, the group had an average of 60 days purchases
outstanding in trade creditors.

Derivatives and other financial instruments
The group’s principal financial instruments comprise convertible loans, bank loans, cash and short-term
deposits. The main purpose of these financial instruments is to secure funds and manage cash flow for the
group’s operations. The group has various other financial instruments such as trade debtors and trade
creditors that arise directly from its operations. Details of financial instruments as required by FRS13 are
disclosed in note 20. The disclosures exclude short term debtors and creditors.

It is, and has been throughout the period under review, the group’s policy that no trading in financial
instruments shall be undertaken.

The main risks arising from the group’s financial instruments are interest rate risk, liquidity risk and foreign
currency risk as summarized below. The board reviews and agrees policies for managing each of these
risks.These policies have remained unchanged during 1998 and 1999.

Interest rate risk
On 28 July 1998, the former PolyDoc business issued £1,570,920 Convertible Loan Stock in order to fund
the working capital requirements of the business. The loan stock bears an interest rate of 5% and was
repayable or convertible on 31 July 1999. Following agreement between the Company and the Loan
Stockholders the redemption date and the conversion date for the Convertible Loan Stock was moved
from 31 July 1999 to 31 July 2000.

The former AppliedNet business had a bank loan which remains outstanding at year end and bears interest
at a floating rate. The group also has overdraft facilities in UK Sterling, US Dollar and Dutch Guilder at
floating rates of interest.

Where the group has significant cash resources available that are in excess of the short term needs of the
business, such funds are maintained in sterling and are placed on short and medium term bank deposit at
the best interest rate available.

Liquidity risk
The group’s objective is to maintain a balance between continuity of funding and flexibility through the use
of overdrafts and bank loans. Short term flexibility is achieved by overdraft facilities.

Foreign currency risk
As a result of having significant operating units in the USA and the Netherlands, which give rise to short
term creditors, debtors and cash balances in US Dollars and Dutch Guilders, the group’s balance sheet can
be affected by movements in the US Dollar/Sterling and Dutch Guilder/Sterling exchange rates.

DIRECTORS REPORT

21

Events since the balance sheet date
Pro-GRAM investment
Since the year end, and as alluded to in previous reports, the group has committed funds of £430,000 for a
25% equity stake in ProGram BV, a company established with a number of Dutch healthcare institutions to
market knowledge management solutions incorporating Sopheon’s software to the Dutch healthcare
industry.

£20m Placing
On 3 March 2000 the Company announced the raising of £20 million through the institutional placing of
2,500,000 ordinary shares at £8.00. These funds will be used to support the group’s acquisition strategy in
the USA and to further strengthen its working capital base to accelerate the sales and marketing effort on
both sides of the Atlantic. Sopheon’s Broker, Durlacher has used all of its proceeds of commissions due
under the placing to subscribe for shares in Sopheon at the placing price. Including certain other adviser
fees settled through the issue of shares at the placing price, this resulted in a further 122,500 shares being
issued at the placing price pursuant to this transaction.

Proposed acquisition of Teltech
On the same date Sopheon announced that it had entered into an agreement to acquire Teltech Resource
Network Corporation. The completion of the acquisition of Teltech would give Sopheon significant
operations in the Netherlands, UK and the USA.

Teltech is a knowledge management and research services company based in Minneapolis, USA, which uses
web technology to deliver its products and services to its customers through vertical internet portals as
well as through more traditional routes. It was founded in 1984 with the current management being
appointed in 1997. In early 1999,Teltech became a Sopheon business partner and the first joint software
and services sales have been achieved. Currently,Teltech is experiencing good growth in revenues, having
made substantial investment in the development of its knowledge portal technologies, launched into the
market as Teltech.com in September 1999.Teltech has a ‘blue chip’ client base, which includes half of the
Fortune 500 companies. In the year ended 31 December 1999,Teltech’s revenues were $16.2 million
(£10.1 million) and it had a loss of $0.09 million (£0.06 million). Teltech had net liabilities of $1.7 million
(£1 million) at 31 December 1999.

The consideration for the Teltech acquisition is for a minimum of $20 million (£12.5 million) in new
Ordinary Shares and options and $15 million (£9 million) in cash. Included in the cash element of the
consideration is $1 million (£0.6 million) that would, as a result of the deal structure, be injected into the
Teltech balance sheet at completion. The cash element of the proposed transaction, associated costs, and
the development of the enlarged US business that would result is being funded through the £20 million
placing referred to above.

Directors and employees of Teltech receiving Sopheon shares or options will undertake to retain them for
12 months and all other investors in Teltech, other than those with a minimal holding, will undertake not
to dispose of any of their Sopheon shares for 6 months.

Completion of the acquisition of Teltech by Sopheon is subject to Securities and Exchange Commission
approvals as well as Teltech shareholder approval, although the board of Teltech, which represents over
50% of Teltech’s shares on a fully diluted basis, has already given its approval.

Other Share Issues
Since the year end 455,000 ordinary shares in Sopheon plc have been issued for £91,000 in cash to option
holders exercising their options, giving rise to a premium of £68,250. Of these options, 400,000 were held
by R.V. Maddocks, a director.

Auditors
A resolution to reappoint Ernst & Young as auditors will be put to the members at the Annual General
Meeting.

Approved by the Board on 28 April 2000

E.R.E.I.Wiebenga 
Secretary

22

STATEMENT OF DIRECTORS’ RESPONSIBILITIES IN RESPECT OF THE ACCOUNTS

Statement of Directors’ responsibilities in 
respect of the accounts

Company law requires the directors to prepare accounts for each financial year which give a true and fair
view of the state of affairs of the company and of the group and of the profit or loss of the group for that
year. In preparing those accounts, the directors are required to:

select suitable accounting policies and then apply them consistently;

(cid:2) make judgements and estimates that are reasonable and prudent;

state whether applicable accounting standards have been followed,
subject to any material departures disclosed and explained in the accounts;
prepare the accounts on a going concern basis unless it is inappropriate to presume 
that the company will continue in business;

The directors are responsible for keeping proper accounting records which disclose with reasonable
accuracy at any time the financial position of the company and to enable them to ensure that the 
accounts comply with the Companies Act 1985. They are also responsible for safeguarding the assets 
of the company and hence for taking reasonable steps for the prevention and detection of fraud and 
other irregularities.

(cid:2)
(cid:2)
(cid:2)
AUDITORS’ REPORT TO THE SHAREHOLDERS OF SOPHEON PLC (FORMERLY POLYDOC PLC)

23

Auditors’ Report to the Shareholders of
Sopheon plc (formerly Polydoc plc)

We have audited the accounts on pages 24 to 46 which have been prepared under the historical cost
convention and the accounting policies set out on page 28.

Respective responsibilities of directors and auditors 
The directors are responsible for preparing the annual report. As described on page 22, this includes
responsibility for preparing the accounts in accordance with applicable United Kingdom law and accounting
standards. Our responsibilities, as independent auditors, are established in the United Kingdom by statute,
the Auditing Practices Board and by our profession’s ethical guidance.

We report to you our opinion as to whether the accounts give a true and fair view and are properly
prepared in accordance with the Companies Act. We also report to you if, in our opinion, the directors’
report is not consistent with the accounts, if the company has not kept proper accounting records, if we
have not received all the information and explanations we require for our audit, or if the information
specified by law regarding directors’ remuneration and transactions with the group is not disclosed.

We read the other information contained in the Annual Report and consider whether it is consistent with
the audited accounts. We consider the implications for our report if we become aware of any apparent
misstatements or material inconsistencies with the accounts.

Basis of audit opinion 
We conducted our audit in accordance with Auditing Standards issued by the Auditing Practices Board.
An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the
accounts. It also includes an assessment of the significant estimates and judgements made by the directors
in the preparation of the accounts, and of whether the accounting policies are appropriate to the group’s
circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we
considered necessary in order to provide us with sufficient evidence to give reasonable assurance that 
the accounts are free from material misstatement, whether caused by fraud or other irregularity or error.
In forming our opinion we also evaluated the overall adequacy of the presentation of information in the
accounts.

Opinion
In our opinion the accounts give a true and fair view of the state of affairs of the company and of the
group at 31 December 1999 and of the loss of the group for the year then ended and have been properly
prepared in accordance with the Companies Act 1985.

Ernst & Young
Registered Auditor
Reading

28 April 2000

24

GROUP PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 1999

Group Profit and Loss Account for the Year
Ended 31 December 1999

Continuing
Operations
1999
£’000

874
(676)
––––––––
198
(659)
(1,225)
16
––––––––
(1,670)

Acquisitions
1999
£’000

636
(307)
––––––––
329
(101)
(574)
-
––––––––
(346)

Notes

2

3

TURNOVER
Cost of sales

GROSS PROFIT/(LOSS)
Sales and marketing expenses
Administrative expenses
Other operating income

OPERATING LOSS
Bank interest receivable
Interest payable and similar charges

LOSS ON ORDINARY ACTIVITIES  
BEFORE AND AFTER TAXATION

Loss per share - basic and diluted (pence)

8

LOSS ON AN EBITDA BASIS

Total
1999
£’000

Restated
1998
£’000

1,510
(983)
––––––––
527
(760)
(1,799)
16
––––––––
(2,016)
62
(118)
––––––––

891
(608)
––––––––
283
(502)
(913)
29
––––––––
(1,103)
13
(52)
––––––––

(2,072)
––––––––

(1,142)
––––––––

(10.1p)
––––––––

(6.1p)
––––––––

(1,654)
––––––––

(1,031)
––––––––

EBITDA represents earnings before interest, tax, depreciation and amortisation.

GROUP STATEMENT OF TOTAL RECOGNIZED GAINS AND LOSSES FOR THE YEAR ENDED 
31 DECEMBER 1999 

Loss on ordinary activities after taxation
Exchange difference on retranslation 
of net assets of subsidiary undertakings

Total recognized gains and losses relating to the year
Prior year adjustment

Total gains and losses recognized since last annual report

Notes

1999
£’000

Restated
1998
£’000

(2,072)

(1,142)

(45)
––––––––

47
––––––––

19

(2,117)
(373)
––––––––

(1,095)
-
––––––––

(2,490)
––––––––

(1,095)
––––––––

GROUP BALANCE SHEET AT 31 DECEMBER 1999

25

Group Balance Sheet at 31 December 1999

FIXED ASSETS
Intangible assets
Tangible assets

CURRENT ASSETS
Debtors
Cash at bank and in hand

CREDITORS: amounts falling due within one year

NET CURRENT ASSETS/(LIABILITIES)

TOTAL ASSETS LESS CURRENT LIABILITIES

CREDITORS: amounts falling due after more than one year

CAPITAL AND RESERVES
Called up share capital
Shares to be issued
Share premium account
Profit and loss account

Shareholders’ funds (all equity interests)

Barry K. Mence
Executive Chairman
28 April 2000

Notes

9
10

12
13

14

1999
£’000

7,605
386
––––––––
7,991

1,362
7,751
––––––––
9,113

3,570
––––––––
5,543
––––––––
13,534

Restated
1998
£’000

167
203
––––––––
370

127
674
––––––––
801

2,032
––––––––
(1,231)
––––––––
(861)

15

55
––––––––

3
––––––––

13,479
––––––––

(864)
––––––––

17
18
18
18

4,491
10
17,960
(8,982)
––––––––

3,773
15
2,213
(6,865)
––––––––

13,479
––––––––

(864)
––––––––

26

COMPANY BALANCE SHEET AT 31 DECEMBER 1999

Company Balance Sheet at 31 December 1999

FIXED ASSETS
Investments

CURRENT ASSETS
Debtors
Cash at bank and in hand

CREDITORS: amounts falling due within one year

NET CURRENT ASSETS

TOTAL ASSETS LESS CURRENT LIABILITIES

CAPITAL AND RESERVES
Called up share capital
Shares to be issued
Share premium account
Profit and loss account

Shareholders’ funds (all equity interests)

Barry K. Mence
Executive Chairman
28 April 2000

Notes

11

12

14

17
18
18
18

1999
£’000

13,211

1998
£’000

4,777

4,216
6,984
––––––––
11,200

1,955
––––––––
9,245
––––––––

2,737
95
––––––––
2,832

1,613
––––––––
1,219
––––––––

22,456
––––––––

5,996
––––––––

4,491
10
17,960
(5)
––––––––

3,773
15
2,213
(5)
––––––––

22,456
––––––––

5,996
––––––––

GROUP STATEMENTS OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 1999

27

Group Statements of Cash Flows for the Year
Ended 31 December 1999

NET CASH OUTFLOW FROM OPERATING ACTIVITIES

RETURN ON INVESTMENTS AND SERVICING OF FINANCE
Interest received
Interest paid
Interest element of finance lease rental payments

CAPITAL EXPENDITURE & FINANCIAL INVESTMENT
Payments to acquire tangible fixed assets

ACQUISITIONS AND DISPOSALS
Purchase of subsidiary undertaking
Net cash acquired with subsidiary undertaking

MANAGEMENT OF LIQUID RESOURCES
(Increase) in short term deposits

NET CASH OUTFLOW BEFORE FINANCING

FINANCING
Issue of ordinary share capital
New long term loan
Repayment of long term loan
Repayment of capital element of finance lease

Notes

1999
£’000

Restated
1998
£’000

3

(1,278)
––––––––

(946)
––––––––

62
(116)
(2)
––––––––
(56)

13
(50)
(2)
––––––––
(39)

(52)
––––––––

(52)
––––––––

(179)
389
––––––––
210

(95)
2
––––––––
(93)

(6,602)
––––––––
(7,778)

(401)
––––––––
(1,531)

8,265
4
-
(16)
––––––––
8,253
––––––––

110
1,571
(299)
(12)
––––––––
1,370
––––––––

INCREASE/(DECREASE) IN CASH

13

475
––––––––

(161)
––––––––

28

NOTES TO THE ACCOUNTS

1  Accounting Policies

Accounting convention
The accounts are prepared under the historical cost convention and in accordance with applicable
accounting standards.

Basis of consolidation
The consolidated accounts include the results of the company and its subsidiary undertakings.
The results of AppliedNet Limited have been included since the date of acquisition, 22 November 1999.

Tangible fixed assets
Tangible fixed assets are stated at historical cost, less accumulated depreciation. Tangible fixed assets are
depreciated on a straight line basis at rates ranging from 20% to 33% per annum on cost over their
expected useful lives.

Research and development
Research and development expenditure is written off as incurred. The cost of registering patents and
trademarks are written off as incurred. Subsidies received from the European Eureka funding programme
are credited to the profit and loss account over the period to which they relate.

Prior year adjustment
Historically, development expenditure incurred for specific products was capitalized when its future
recoverability could reasonably have been regarded as assured, and amortized in line with the expected
future sales from the related product, to a maximum of 5 years. Following the acquisition of AppliedNet
Limited and subsequent harmonization of group accounting policies, all such expenditure is now written 
off as incurred. The effect of changing this policy has been reflected by way of a prior year adjustment to
the 1998 financial statements of the group.

Goodwill
Goodwill arising on consolidation is capitalized and amortized on a straight line basis over its estimated
useful economic life, currently estimated at 3 to 5 years depending on circumstances. Goodwill is reviewed
for impairment at the end of the first full financial year after acquisition and in other periods if events or
changes in circumstances indicate that carrying values may not be recoverable. If a subsidiary, associate or
business is subsequently sold or closed, any goodwill arising on acquisition that has not been amortized is
taken into account in determining the profit or loss on sale or closure.

Foreign currencies
Company
Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction or at the
contracted rate if the transaction is covered by a forward exchange contract. Monetary assets and liabilities
denominated in foreign currencies are retranslated at the rate of exchange ruling at the balance sheet date
or if appropriate at the forward contract rate. All differences are taken to the profit and loss account.

Group
The assets and liabilities of the subsidiary undertakings are translated at the rate of exchange ruling at the
balance sheet date. The profit and loss account is translated at the average rate of exchange. The exchange
differences arising on the re-translation of subsidiary undertakings are, together with differences arising 
on the translation of long term intra-group funding loans which are not intended to be repaid in the
foreseeable future, taken directly to reserves. All other differences are taken to the profit and loss account.

Long term contracts
Profit on long term contracts is taken as the work is carried out if the outcome can be assessed with
reasonable certainty. The profit included is calculated on a prudent basis to reflect the proportion of the
work carried out at the year end, by recording turnover and related costs as contract activity progresses.
Turnover is calculated as that proportion of total contract value which costs incurred to date bear to 
total expected costs for that contract. Revenues derived from variations on contracts are recognized 
only when the customer has accepted them. Full provision is made for losses on all contracts in the 
year in which they are first foreseen.

Pensions
Sopheon contributes to the personal pension arrangements of employees, the costs of which are charged
in the profit and loss account as incurred.

NOTES TO THE ACCOUNTS

29

Leasing
Assets held under finance leases, which are leases where substantially all risks and rewards of ownership 
of the assets have passed to the group, are capitalized in the balance sheet and are depreciated over their
useful lives. The capital elements of future obligations under financial leases are included as liabilities in the
balance sheet. The interest element of the rental obligations are charged to the profit and loss account
over the period of the lease and represent a constant proportion of the balance of capital repayments
outstanding. Rentals payable under operation leases are charged in the profit and loss account on a
straight line basis over the lease term.

2  Turnover and segmental information

Turnover (excluding valued added tax) represents the amounts derived from the group’s principal activity
which comprises the design, development, production and marketing of knowledge management software
products together with associated implementation services. It operates within three geographical markets,
the Netherlands, the United Kingdom and the United States of America.

Analysis of turnover by geographical destination

United Kingdom
The Netherlands
United States of America

Analysis of turnover and operating loss by geographical origin

Operating loss
Restated
1998
£’000

1999
£’000

346
1,414
256
––––––––
2,016
––––––––

-
1,103
-
––––––––
1,103
––––––––

United Kingdom
The Netherlands
United States of America

Analysis of net assets by geographical origin

United Kingdom
The Netherlands
United States of America
Unallocated cash and loans at group level

1999
£’000

1998
£’000

693
777
40
––––––––
1,510
––––––––

166
722
3
––––––––
891
––––––––

Turnover

1998
£’000

-
891
-
––––––––
891
––––––––

Restated
1998
£’000

-
707
-
(1,571)
––––––––
(864)
––––––––

1999
£’000

636
874
-
––––––––
1,510
––––––––

1999
£’000

8,054
89
(76)
5,412
––––––––
13,479
––––––––

30

NOTES TO THE ACCOUNTS

3  Operating loss

(a) This is stated after charging/(crediting):

Auditors’ remuneration - audit services
Auditors’ remuneration - non audit services
Research and development expenditure written off
Eureka subsidies
Foreign exchange differences
Depreciation of owned assets
Depreciation of assets held under finance leases
Operating lease rentals - land and buildings
Operating lease rentals - motor vehicles

1999
£’000

1998
£’000

34
13
878
(315)
16
74
9
103
84
––––––––

20
3
815
(304)
(29)
63
9
94
79
––––––––

During 1999 £64,000 was charged by the auditors in respect of work associated with due diligence and
fund raising which has been capitalized or written off to share premium as appropriate.

The 1998 results have been restated to reflect the prior year adjustment described in note 19, whereby
development costs that have been capitalized and amortized in the past are now written off as they arise.
The results have also been restated whereby certain costs, mainly relating to internal research and
development activities, have been reallocated from cost of sales to administration costs. Both of these
changes were undertaken to bring accounting policies and disclosures into line on a group basis following
the acquisition of AppliedNet Limited. Finally, in the 1998 and previous accounts, amounts disclosed as
research and development costs written off included cost of sales items relating to customer led projects
that were developmental in nature. The disclosures above exclude these costs.

Had the same allocation of costs been used, and had the prior year adjustment not been recorded,
consolidated research and development costs would have been reported as £1,391,000 (1998 -
£1,197,000) and consolidated cost of sales would have been reported as £1,383,000 (1998 - £892,000).

Reconciliation of operating loss to net cash outflow from operating activities

Operating loss
Depreciation
Amortisation
Decrease in debtors
Increase/(decrease) in creditors and provisions
Exchange movements

Net cash outflow from operating activities

1999
£’000

1998
£’000

(2,016)
83
323
(338)
715
(45)
––––––––
(1,278)
––––––––

(1,103)
72
-
9
30
46
––––––––
(946)
––––––––

4  Staff costs

Wages and salaries
Social security costs
Other pension costs

The fees and emoluments of all directors were as follows:

Fees
Other emoluments
Salary
Benefits
Pension contributions

NOTES TO THE ACCOUNTS

31

1999
£’000

1998
£’000

1,231
124
42
––––––––
1,397
––––––––

857
74
29
––––––––
960
––––––––

1999
£’000

1998
£’000

24
25
235
49
15
––––––––
348
––––––––

19
29
238
47
15
––––––––
348
––––––––

Pension contributions are to personal defined contribution schemes and are made for five directors.
The emoluments of the highest paid director were as follows:

Basic Salary
Benefits
Pension contributions to defined contribution scheme

Total

1999
£’000

1998
£’000

78
16
7
––––––––
101
––––––––

79
16
7
––––––––
102
––––––––

The average monthly number of employees during the year was made up as follows:

Development and operations
Sales and management

1999
Number

1998
Number

26
14
––––––––
40
––––––––

21
10
––––––––
31
––––––––

32

NOTES TO THE ACCOUNTS

5  Interest payable and similar charges

Bank loans and overdrafts
Convertible loan stock
Finance charges on finance leases

6  Taxation

1999
£’000

1998
£’000

39
78
1
––––––––
118
––––––––

16
34
2
––––––––
52
––––––––

There was no tax charge for 1999 or 1998. Tax losses are available for carry forward by the Group 
the amount of which is under discussion with the relevant authorities in the UK and the Netherlands.
In accordance with the group’s policy no provision has been made for the potential deferred tax asset 
on these losses.

7  Loss attributable to members of the parent company

The loss dealt with in the accounts of the parent company for 1999 was £nil (1998 - £nil). Advantage 
has been taken of Section 230 of the Companies Act 1985 not to present a profit and loss account for 
the parent company.

8  Loss per ordinary share

The calculation of basic loss per ordinary share is based on a loss of £2,072,000 (1998 – £1,142,000 as
restated) and 20,565,985 (1998 – 18,730,633) ordinary shares, being the weighted average number of
ordinary shares in issue during the year.

The effect of all potential ordinary shares is antidilutive in 1998 and 1999.

The historic earnings per share calculations are not affected by the restructuring of share capital described
in note 17 below because the total number of ordinary shares in issue did not change as a result of the
restructuring.

9  Intangible fixed assets

Group only

COST
At 1 January 1999
Prior year adjustment
Adjustment
Additions

At 31 December 1999

AMORTISATION
At 1 January 1999
Prior year adjustment
Provided during the year

At 31 December 1999

NET BOOK VALUE
At 31December 1999

At 31December 1998
Prior year adjustment

At 31 December 1998 (restated)

NOTES TO THE ACCOUNTS

33

Goodwill
£’000

Development
costs
£’000

167
-
(5)
7,766
––––––––
7,928
––––––––

466
(466)
-
-
––––––––
-
––––––––

Total
£’000

633
(466)
(5)
7,766
––––––––
7,928
––––––––

-
-
323
––––––––
323
––––––––

93
(93)
-
––––––––
-
––––––––

93
(93)
323
––––––––
323
––––––––

7,605
––––––––

-
––––––––

7,605
––––––––

167
-
––––––––
167
––––––––

373
(373)
––––––––
-
––––––––

540
(373)
––––––––
167
––––––––

The prior year adjustment is discussed in note 19. The other adjustment represents reduction in
contingent consideration payable for Lessenger Associates BV as described in note 11.

34

NOTES TO THE ACCOUNTS

10  Tangible fixed assets

Group only

COST
At 1 January 1999
Exchange adjustments
Acquired with subsidiary undertaking
Additions

At 31 December 1999

DEPRECIATION
At 1 January 1999
Exchange adjustments
Acquired with subsidiary undertaking
Provided during the year

At 31 December 1999

NET BOOK VALUE
At 31 December 1999

At 31 December 1998

Computer
Equipment
£’000

Furniture
& fittings
£’000

282
(32)
324
69
––––––––
643
––––––––

149
(20)
158
57
––––––––
344
––––––––

299
––––––––
133
––––––––

117
(13)
58
2
––––––––
164
––––––––

47
(6)
11
25
––––––––
77
––––––––

87
––––––––
70
––––––––

Total
£’000

399
(45)
382
71
––––––––
807
––––––––

196
(26)
169
82
––––––––
421
––––––––

386
––––––––
203
––––––––

The net book value of furniture and fittings above includes an amount of £18,000 (1998 – £27,000) in
respect of assets held under finance leases.

11  Investments

Company

COST
At 1 January 1999
Adjustment to consideration for Lessenger (see below)
Additions

At 31 December 1999

NOTES TO THE ACCOUNTS

35

Investment in 
subsidiary 
undertakings
£’000

4,777
(5)
8,439
––––––––
13,211
––––––––

The group acquired Lessenger Associates BV in 1998 and included in the consideration was up to a
maximum of 10,000 shares to be issued at £1.46 contingent on certain conditions based on 1999
performance. These conditions were not met in full and only 7,114 shares are required to be issued,
reducing the contingent consideration to £10,386.

On 22 November 1999 the group completed the acquisition of AppliedNet Limited (renamed Sopheon UK
Limited) for consideration of 6,402,961 ordinary shares of Sopheon plc in respect of the entire ordinary
share capital of AppliedNet and cash of £11,000 in respect of its entire preference share capital, as well as
attributed costs of £168,000. The market value of Sopheon plc’s ordinary shares on 27 October 1999, the
date the acquisition became unconditional, was 129p. Accordingly, the total cost recorded in respect of the
acquisition was £8,439,000.

Analysis of the acquisition of AppliedNet Limited:

Book and fair value
£’000

Tangible fixed assets
Debtors
Cash

Creditors falling due within one year
Creditors falling due in more than one year

Net assets
Goodwill arising on acquisition

Discharged by:
Fair value of shares issued
Attributable costs
Cash

213
899
389
––––––––
1,501
(826)
(2)
––––––––
673
7,766
––––––––
8,439
––––––––

8,260
168
11
––––––––
8,439
––––––––

In the view of the directors there were no fair value adjustments required. AppliedNet Limited had a loss
before tax of £1,097,000 in the 15 months ended 31 December 1999 (year ended 30 September 1998
profit before tax of £208,000). There was turnover of £2,693,000 and a loss before and after tax of
£1,002,000 in the period 1 October 1998 to 22 November 1999. There were no recognized gains and
losses other than the loss for the period.

36

NOTES TO THE ACCOUNTS

11  Investments (continued)

Details of the investments in which the group or company holds more than 20% of the nominal value of
any class of share capital are set out below. Companies marked with an asterisk * are held via Sopheon UK
Limited (formerly AppliedNet Limited).

Name of Company
Country of incorporation

Holding

Proportion of
voting rights

Nature of Business

Sopheon NV
The Netherlands

Lessenger BV
The Netherlands

Sopheon UK Ltd
United Kingdom

Ordinary Shares

100%

Ordinary Shares

100%

Ordinary Shares

100%

Network Managers (UK) Ltd
United Kingdom*

Ordinary Shares

100%

Knowledge management
software and services

Document management
software and services

Knowledge management
software and services

Network management
software and services

Futuretense UK Ltd
United Kingdom*

Futuretense Ltd
United Kingdom*

SageWare Europe Ltd
United Kingdom*

Ordinary Shares

100%

Dormant

Ordinary Shares

100%

Dormant

Ordinary Shares

100%

Dormant

Applied Network Technology Ltd
United Kingdom*

Ordinary Shares

100%

Employee Share Ownership
Trust

12  Debtors

Group

Trade debtors
Other debtors
Prepayments and accrued income

Company

Amounts owed by subsidiary undertakings
Other debtors

1999
£’000

1998
£’000

1,104
86
172
––––––––
1,362
––––––––

85
-
42
––––––––
127
––––––––

1999
£’000

1998
£’000

4,200
16
––––––––
4,216
––––––––

2,737
-
––––––––
2,737
––––––––

13  Notes to Statement of Cash Flows

(a) Reconciliation of net cash flow to movement in net funds.

(Decrease)/increase in cash
Repayment of long term loans
New loans
Cash inflow from increase in debt
Repayments of capital elements of finance leases
Cash inflow/(outflow) from change in liquid resources

Change in net debt resulting from cash flows
Loans and finance leases acquired with subsidiary

Movement in net funds/(debt)

Net funds/(debt) at 1 January 

Net funds/(debt) at 31 December

(b) Analysis of changes in net funds

NOTES TO THE ACCOUNTS

37

1999
£’000

1998
£’000

475
4
(8)
-
16
6,602
––––––––
7,089
(92)
––––––––
6,997
––––––––
(917)
––––––––
6,080
––––––––

(161)
299
-
(1,571)
12
401
––––––––
(1,020)
-
––––––––
(1,020)
––––––––
103
––––––––
(917)
––––––––

Cash at
bank

£’000

272
475
-
––––––––
747
––––––––

Short term 
deposits/
liquid
resources*
£’000

402
6,602

––––––––
7,004
––––––––

Term
loans

Convertible
loan stock

Finance
leases

Total

£’000

£’000

£’000

£’000

-
(4)
(86)
––––––––
(90)
––––––––

(1,571)
-
-
––––––––
(1,571)
––––––––

(20)
16
(6)
––––––––
(10)
––––––––

(917)
7,089
(92)
––––––––
6,080
––––––––

At 1 January 1999
Cashflow 
Acquisitions

At 31 December 1999

*Short term deposits/liquid resources are included within cash at bank and in hand on the balance sheet.

38

NOTES TO THE ACCOUNTS

14  Creditors: amounts falling due within one year

Group

Convertible loan stock 5%
Current installments due on bank loan
Obligations under finance leases
Trade creditors
Other taxes and social security costs
Accruals and deferred income
Other creditors

1999
£’000

1998
£’000

1,571
28
8
619
241
708
395
––––––––
3,570
––––––––

1,571
-
17
306
25
113
-
––––––––
2,032
––––––––

The convertible loan stock carries an interest rate of 5% and was issued to the company’s three largest
shareholders on 31 July 1998. It was repayable or convertible into ordinary shares at a conversion price 
of £1.46 on 31 July 1999, at the option of the loan stockholders. On 12 April 1999, the repayment or
conversion option was extended by the loan stockholders to 31 July 2000. Interest on the convertible 
loan stock is payable on 30 June and 31 December.

Company

Convertible loan stock 5%
Other creditors
Other taxes and social security costs
Accruals

1999
£’000

1998
£’000

1,571
373
10
1
––––––––
1,955
––––––––

1,571
-
2
40
––––––––
1,613
––––––––

15  Creditors: amounts falling due after more than one year

Group

Obligations under finance leases
Bank loan

1999
£’000

1998
£’000

1
54
––––––––
55
––––––––

3
-
––––––––
3
––––––––

The bank loan is a UK asset purchase facility at an implicit rate of 8.8% and is repayable in 36 equal
installments from October 1999.

16  Obligations under leases

Amounts due under finance leases and hire purchase contracts:
Group only

Amounts payable:
Within one year
In two to five years

Less finance charges allocated to future periods

NOTES TO THE ACCOUNTS

39

1999
£’000

1998
£’000

8
1
––––––––
9
-
––––––––
9
––––––––

17
4
––––––––
21
1
––––––––
20
––––––––

The company had no amounts due under finance leases and hire purchase contracts. At 31 December
1998 and 1999 the group had annual commitments under operating leases as set out below.

Group

Operating leases which expire:
within one year
in two to five years

Totals

Other
1999
£’000

64
97
––––––––
161
––––––––

Land &
buildings
1999
£’000

176
51
––––––––
227
––––––––

Other
1998
£’000

26
63
––––––––
89
––––––––

Land &
buildings
1998
£’000

-
100
––––––––
100
––––––––

The company had commitments under operating leases as at 31 December 1999 amounting to £12,000
(1998 - £4,000) expiring within one year and £nil expiring within two to five years (1998 - £12,000).

17  Share capital

Authorized

Ordinary shares of 20p each 
Ordinary shares of 5p each
Deferred shares of 15p each

Allotted, called up and fully paid

Ordinary shares of 20p each 
Ordinary shares of 5p each
Deferred shares of 15p each

1999
Number

1999
£

1998
Number

1998
£

-
42,902,961
19,228,885
––––––––

-
6,645,148
2,884,333
––––––––

30,000,000
-
-
––––––––

6,000,000
-
-
––––––––

1999
Number

1999
£

1998
Number

1998
£

-
32,131,846
19,228,885
––––––––
51,360,731
––––––––

-
1,606,592
2,884,333
––––––––
4,490,925
––––––––

18,863,885
-
-
––––––––
18,863,885
––––––––

3,772,777
-
-
––––––––
3,772,777
––––––––

40

NOTES TO THE ACCOUNTS

17  Share capital (continued)

On 15 October 1998, 30,000 ordinary shares were issued for cash at 20p each. On 20 October 1998
10,000 were allotted for cash to an exercising holder of share options at 20p each. On 9 December 1998
68,500 ordinary shares of 20p each were issued at £1.46 for cash and a further 40,000 ordinary shares 
of 20p each were issued at £1.46 as part consideration for the acquisition of Lessenger Associates BV.
As described in note 11 a further 7,114 ordinary shares will be issued to the vendors of Lessenger
Associates BV in connection with a contingent consideration arrangement.

An Extraordinary General Meeting of the Company held on 28 July 1998, approved the subscription of
each of B.K. Mence, NPM Capital NV and Brandon Limited, of £523,640 5% Convertible Loan Stock at par
the conversion terms of which are described in note 14, as well as the award of 300,000 Warrants each.
The Warrants did not attract any consideration. Each Warrant entitles the holder to subscribe on or
before 31 December 2000, for the one Ordinary Share of £1.46 per share.
the Warrants shall lapse.

If not exercised by that date

On 20 January 1999 5,000 ordinary shares were issued for cash to an exercising holder of share options at
20p each. On 10 March 1999 340,000 ordinary shares were issued to institutions for cash at a price of
£1.47 per share. On 28 April 1999 20,000 ordinary shares were issued for cash to an exercising holder of
share options at 20p each.

On 22 November 1999 in an Extraordinary General Meeting of the Shareholders the share capital of
Sopheon plc was restructured such that each ordinary share of 20p was converted into one ordinary
share of 5p and one deferred share of 15p. The deferred shares carry no rights as to dividend, voting or
return of capital on liquidation, and are not listed on any exchange.The number of ordinary shares in issue
did not change as a consequence of the restructuring. Similarly, the number, exercise price and other 
terms of any share options over Ordinary Shares of 20p each remained unchanged as a consequence of
the restructuring.

On the same date 6,500,000 ordinary shares of Sopheon plc were placed with institutions at a price of
125p per ordinary share, realizing net proceeds after attributed costs of £7,699,000. Furthermore as
referred to in note 11, 6,402,961 ordinary shares of Sopheon plc were issued as consideration for the
acquisition of 100% of the ordinary share capital of AppliedNet Limited, at a price of 129p per ordinary
share.

Share option scheme
The directors have specified a maximum of 5% of ordinary shares over which options could be granted
under any employee share option scheme. Share options are granted by the Board of directors on a
discretionary basis under the terms of various schemes as summarized below.

On 28 August 1996 the directors adopted, and the company in general meeting approved, a share option
scheme to provide for the grant to certain directors and employees of PolyDoc NV of options over
Ordinary Shares in exchange for the surrender by such directors and employees of their existing options
over shares in PolyDoc NV. The scheme also provided for the grant by the company of subsequent new
options over Ordinary Shares to employees of the Group. On the same date the directors adopted, and
the company in general meeting approved, an executive share option scheme in a form approved by the
Inland Revenue.

NOTES TO THE ACCOUNTS

41

Since the establishment of the schemes several option grants have been made. None of the grants 
have been made under the Inland Revenue approved scheme however in the majority of cases the rights 
of the options granted have been consistent with the rights they would have had under that scheme.
Certain grants, in particular those relating to employees in the USA, have involved different vesting
arrangements whereby employees are entitled to exercise a proportion of their options each year rather
than have all of them becoming exercisable at a particular date.

Pursuant to the acquisition of AppliedNet Limited, all options granted under the AppliedNet unapproved
share option scheme were released in exchange for the grant of new options over shares in Sopheon plc.
The new options are subject to the rules of the original AppliedNet scheme.

A summary of options granted up to and including 1999 is listed below.

Year of grant

1996
1997
1997
1997
1998
1998
1998 (1)
1999
1999
1999 (1)
1999
1999 (2)
1999 (1)
1999 (1)
1999 (2)(3)
1999
1999 (3)

Number

660,000
10,000
1,000
20,000
36,500
30,000
218,008
17,500
10,000
87,209
65,000
42,500
13,080
74,150
75,000
50,000
100,000

Exercise
Price

Convertible
From

Convertible
To

0.2000
0.8950
1.9750
1.7750
1.7000
1.7000
0.0860
1.4150
1.4150
0.0860
1.5000
1.5000
0.8732
0.8732
1.5000
1.5000
1.5000

28-08-96
04-02-00
01-06-00
01-07-00
29-06-98
29-06-01
29-12-01
20-01-02
20-01-99
04-03-02
28-04-99
28-04-00
01-06-02
01-10-02
03-11-00
03-11-02
22-11-02

21-07-01
04-02-07
01-06-07
01-07-07
29-06-03
29-06-08
29-12-08
20-01-09
20-01-04
04-03-09
28-04-04
28-04-09
01-06-09
01-10-09
03-11-09
03-11-09
22-11-09

(1) Options arising as a result of options held by employees of AppliedNet and rolled over into Sopheon

options.

(2) One fourth of these options become exercisable each year starting on the date indicated.

All other options become exercisable in full from the date indicated.

(3) Includes options which are contingent upon certain performance targets.

Options granted to directors are specified in the Directors report.

42

NOTES TO THE ACCOUNTS

18  Shareholders’ funds

Group

At 1 January 1998
Arising on share issues
Shares to be issued
Retained loss for the year 
Exchange differences on retranslation
of net assets and results of subsidiary
undertaking

At 31 December 1998
Prior year adjustment

At 31 December 1998 restated
Arising on share issues
Adjustment to earn out
Retained loss for the year 
Exchange differences on retranslation
of net assets and results of subsidiary
undertaking

At 31 December 1999

Share
capital
£’000

3,743
30
-
-

Shares
to be
issued
£’000

-
15
-

Share
Premium
Account
£’000

2,076
137
-
-

Profit &
Loss 
Account
£’000

(5,558)
-
-
(981)

Total
£’000

261
167
15
(981)

-
––––––––
3,773
-
––––––––
3,773
718
-
-

-
––––––––
15
-
––––––––
15
-
(5)
-

-
––––––––
2,213
-
––––––––
2,213
15,747
-
-

47
––––––––
(6,492)
(373)
––––––––
(6,865)
-

(2,072)

47
––––––––
(491)
(373)
––––––––
(864)
16,465
(5)
(2,072)

-
––––––––
4,491
––––––––

-
––––––––
10
––––––––

-
––––––––
17,960
––––––––

(45)
––––––––
(8,982)
––––––––

(45)
––––––––
13,479
––––––––

The prior year adjustment is described in note 19.

The adjustment to earn out represents an adjustment to contingent consideration payable in respect of
Lessenger Associates BV as described in note 11.

Company

At 1 January 1998
Arising on share issues
Shares to be issued

At 31 December 1998
Arising on share issues
Adjustment to earn out

At 31 December 1999

Share
capital
£’000

3,743
30
-
––––––––
3,773
718
-
––––––––
4,491
––––––––

Shares to
be issued
£’000

-
-
15
––––––––
15
-
(5)
––––––––
10
––––––––

Share
Premium
Account
£’000

2,076
137
-
––––––––
2,213
15,747
-
––––––––
17,960
––––––––

Profit &
Loss 
Account
£’000

(5)
-
-
––––––––
(5)
-
-
––––––––
(5)
––––––––

Total
£’000

5,814
167
15
––––––––
5,996
16,465
(5)
––––––––
22,456
––––––––

The adjustment to earn out represents an adjustment to contingent consideration payable in respect of
Lessenger Associates BV as described in note 11.

NOTES TO THE ACCOUNTS

43

19  Prior year adjustment

Historically, development expenditure incurred for specific products was capitalized when its future
recoverability could reasonably have been regarded as assured, and amortized in line with the expected
future sales from the related product, to a maximum of 5 years. Following the acquisition of AppliedNet
Limited and subsequent harmonization of group accounting policies, all such expenditure is now written off
as incurred. The effect of changing this policy has been reflected by way of a prior year adjustment to the
1998 financial statements of the group, and has required a one off adjustment of £373,000 being a net
debit to reserves. If the original policy had been continued, reported operating loss for 1999 would have
been £7,000 higher.

20  Derivatives and other financial instruments

The group’s approach to managing financial risk is described in the Directors Report on pages 18 to 21.

Interest rate risk profile of financial liabilities
Excluding the Convertible Loan Stock which bears a fixed rate of 5% on a nominal value of £1,570,920, all
the financial liabilities of the group at each year or period end are set out below.

Fixed rate loans and overdrafts - Sterling
Fixed rate loans and leases - Dutch Guilder

These financial liabilities bear interest rates that are based on local bank rates.

1999
£ ‘000

1998
£ ‘000

82
9
––––––––
91
––––––––

-
20
––––––––
20
––––––––

44

NOTES TO THE ACCOUNTS

20  Derivatives and other financial instruments (continued)

Interest rate risk profile of financial assets
The financial assets of the group at each year or period end comprise cash or cash deposits on money
market deposit at call and monthly rates.The amounts were as follows:

FLOATING RATE
Sterling
Dutch Guilder
US Dollar

NON-INTEREST BEARING
Sterling
US Dollar
Dutch Guilder

Total financial assets

1999
£ ‘000

1998
£ ‘000

7,004
-
-
––––––––
7,004

496
97
154
––––––––
747
––––––––
7,751
––––––––

-
379
-
––––––––
379

95
-
200
––––––––
295
––––––––
674
––––––––

NOTES TO THE ACCOUNTS

45

Currency exposures
The table below shows the group’s transactional currency exposures that give rise to the net currency
gains and losses recognized in the profit and loss account. Such exposures comprise the monetary assets
and monetary liabilities of the group that are not denominated in the operating currency of the operating
unit involved, and have arisen only in operating units with a functional currency of sterling.

1998 Sterling
1999 Sterling

Net foreign currency monetary assets
Other
Dutch
Currency
Guilder
£ ‘000
£ ‘000

Total
£ ‘000

US dollar
£’000

-
107
––––––––

379
-
––––––––

-
-
––––––––

379
97
––––––––

Maturity of financial liabilities
The maturity profile and interest rates of the group’s financial liabilities at each relevant period or year end
is as set out in Notes 14 and 15.

Borrowing facilities
The group had no undrawn committed facilities available at each relevant period or year end apart from
overdraft facilities.

Fair values of financial assets and liabilities
The fair values of financial assets and liabilities are set out below. Finance leases are included in the 
analysis of long term borrowings.The directors consider that there were no material differences between
the book values and fair values of all the group’s financial assets and liabilities at each year and period end.
As described in note 17, the holders of convertible loan stock are entitled to convert their loan stock and
an additional 900,000 warrants at a price of £1.46 per ordinary share.

Cash and short term deposits
Convertible Loan Stock
Current portion of long term borrowings
Long term borrowings

1999
£ ‘000

7,751
(1,571)
(36)
(55)
––––––––

Book value
1998
£ ‘000

674
(1,571)
(17)
(3)
––––––––

46

NOTES TO THE ACCOUNTS

21  Contingent liabilities

In accordance with Article 403, Paragraph 1, Subsection b, Book 2 of the Dutch Civil Code (B.W.), Sopheon
plc guarantees the liabilities of Sopheon NV and agrees with the departure from the regulations in Title 9
Book 2 of the Dutch Civil Code (B.W.), that prescribes the submission of the accounts of Sopheon NV to
the Trade Register in Holland. As a consequence Sopheon NV need not file its accounts at the Trade
Register.

22  Events since the balance sheet date

Since the year end, and as noted in previous reports, the group has committed funds of £430,000 for a
25% equity stake in ProGram BV, a company established with a number of Dutch healthcare institutions 
to market knowledge management solutions incorporating Sopheon’s software to the Dutch healthcare
industry.

Since the year end 455,000 ordinary shares in Sopheon plc have been issued for £91,000 in cash to option
holders exercising their options, giving rise to a premium of £68,250. Furthermore, since the year end the
directors have approved the grant of options over 82,360 ordinary shares.

A placing of 2,622,500 shares for cash of 800p per share, and a potential acquisition, was announced on 
3 March 2000 further details of which are given in the directors report.

As detailed in the directors’ report, since the year end Sopheon has entered into an agreement to 
acquire Teltech Resource Network Corporation, a knowledge management business based in Minneapolis,
USA for a minimum net consideration of $34 million comprising a combination of cash, shares and options.

www.sopheon.com